WASHINGTON, April 24, 2021 /PRNewswire/ -- On the 106th anniversary of the Armenian Genocide, U.S. President Joe Biden officially affirmed that the massacre of the 1.5 million Armenians at the hands of the Ottoman Turkish authorities between 1915 and 1923 was an act of genocide. This affirmation marks a watershed moment in U.S. history, as it reaffirms what has been U.S. policy since the creation of the 1948 UN Genocide Convention, as reflected in the U.S. brief filed with the International Court of Justice, reported the Armenian Assembly of America (Assembly). It is also a categorical rejection of a decades-long, well-funded denial campaign by the Turkish government and a signature moment for human rights. Releasing his statement on April 24, Armenian Remembrance Day, President Biden honored the symbolic date of the start of the Armenian Genocide, when the leadership of the Armenian community in the Ottoman Empire was arrested, imprisoned and eliminated. Thirty countries and 49 U.S. States have acknowledged the Armenian Genocide. Today's U.S. action is expected to create the room for more countries to follow suit and an opportunity for Turkey to come to terms with its past.The recognition of the Executive Branch results in all three branches of the U.S. government officially affirming the Armenian Genocide, following the overwhelming 405 to 11 vote in the House adopting an Armenian Genocide resolution in October 2019, and by its passage in the Senate via unanimous consent in December 2019. President Biden stayed true to his 30-year documented record of Armenian Genocide acknowledgement, from the time he began serving as Delaware's Senator, through his 2020 presidential campaign, when he pledged: "Joe Biden will recognize the Armenian Genocide and make universal human rights a top priority for his administration so that such a tragedy can never again occur." As a Senator, Biden was among the most informed and diligent supporters in using the term Armenian Genocide. His 1989 chairmanship of the Judiciary Committee's passage of such legislation was historic for its result but also as a reflection of his command of the historical facts.U.S. Ambassador to the Ottoman Empire, Henry Morgenthau, alerted in his July 1915 report to the U.S. Department of State and the White House, that "a campaign of race extermination is in progress under a pretext of reprisal against rebellion." Ambassador Morgenthau, who served from 1913-1916, appealed to the U.S. government and humanitarian organizations to stop the genocide and send humanitarian assistance to the survivors and refugees.
Ambassador Morgenthau's cables, along with eyewitness reports of American consuls, missionaries and businessmen, make up part of the over 30,000 pages documenting the Armenian Genocide, as well as their heroic acts of intervention to save lives. Through his efforts, the Near East Relief was formed, and over $2.5 billion in today's dollars was raised at the time to help the survivors of the first genocide of the twentieth century.At the time, former President Theodore Roosevelt stated that the atrocities committed by the "Turks on the Armenians" was "so hideous that it is difficult to name them…people whose little children are murdered and their women raped." In a letter to Cleveland Dodge, who led the congressionally chartered Near East Relief organization headquartered in New York City, President Roosevelt stated further that it "was the greatest crime of the war, and failure to act against Turkey is to condone it…"Ronald Reagan was the first U.S. president who used the word genocide to describe the Armenian atrocities during his Holocaust Remembrance Statement on April 22, 1981: "Like the genocide of the Armenians before it, and the genocide of the Cambodians which followed it – and like too many other such persecutions of too many other peoples – the lessons of the Holocaust must never be forgotten." President Biden had the courage to say what his predecessors for the past 100 years have always known."The Assembly, all Armenians and our friends around the world profoundly thank President Biden for this Armenian Genocide reaffirmation in honor of the victims, survivors, and the principle of universal human rights around the world," said Assembly Co-Chairs Van Krikorian and Anthony Barsamian. "We have been fortunate to have been helped by countless prominent and not so prominent but heroic individuals in advocating for Genocide awareness, education, and prevention. We are sad that they are not all with us today but know they, like all people who are sincerely committed to human rights, are smiling with pride on President Biden and today's historic statement." "President Biden's statement pays important tribute to the victims of the Armenian Genocide and their families," added Assembly President Carolyn Mugar.
In a September 2019 letter from President Biden to the Assembly, he stated: "The United States must reaffirm, once and for all, our record on the Armenian Genocide...We must never forget or remain silent about this horrific and systematic campaign of extermination that resulted in the deaths of 1.5 million Armenian men, woman, and children and the mass deportation of 2 million Armenians from their homes. If we do not fully acknowledge, commemorate, and teach our children about genocide, the words 'never again' lose their meaning. The facts must be as clear and as powerful for future generations as for those whose memories are seared by tragedy. Failing to remember or acknowledge the fact of a genocide only paves the way for future mass atrocities.""President Biden's affirmation of the Armenian Genocide marks a pivotal milestone in the arc of history in defense of human rights," stated Assembly Executive Director Bryan Ardouny. "By standing firmly against a century of denial, President Biden has charted a new course. Affirmation of the Armenian Genocide enhances America's credibility and recommits the United States to the worldwide cause of genocide prevention."Established in 1972, the Armenian Assembly of America is the largest Washington-based nationwide organization promoting public understanding and awareness of Armenian issues. The Assembly is a non-partisan, 501(c)(3) tax-exempt membership organization. View original content:https://www.prnewswire.com/news-releases/president-bidens-armenian-genocide-reaffirmation-shows-america-at-its-best-301276323.htmlSOURCE Armenian Assembly of America
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE:JNJ) and Roche Holding AG (OTC:RHHBY) each reported fairly robust results.
Four healthcare stocks, including biotechs and medical device makers, debuted on Wall Street this week, raising $413.3 million in gross proceeds.
Ocugen, Inc. (NASDAQ:OCGN) was among the biggest gainers of the week, having advanced over 110% on the back of a positive clinical readout for a partnered COVID-19 vaccine candidate.
Here are the key catalysts for the unfolding week:
International Organization for Medical Physics', or IOMP, International Medical Physics Week: April 26-30UBS Asia Virtual Healthcare Summit: April 27-29B. Riley's Neuroscience Investor Conference: April: April 28—292021 Society of Biological Psychiatry, or SOBP, annual meeting: April 29-May 1Association for Research In Vision and Ophthalmology, or ARVO, 2021 Virtual Meeting: May 1-7
The Food and Drug Administration is scheduled to announce its verdict on Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) new drug application for Epsolay in the treatment of inflammatory lesions of rosacea. The PDUFA date, or the deadline for announcing the decision, is Monday.
The FDA will also rule on Protalix BioTherapeutics, Inc.'s (NYSE:PLX) biologic license application for pegunigalsidase alfa in Fabry disease. The PDUFA date is set for Tuesday.
By Thursday, the regulatory agency is mandated to make a decision on Ardelyx, Inc.'s (NASDAQ:ARDX) new drug application for tenapanor in hyperphosphatemia.
Related Link: BofA Says GlaxoSmithKline's Decision To Halt Feladilimab Studies Is Disappointing
Nanobiotix S.A. (NASDAQ:NBTX) is scheduled to present at the IOMP's physics week, further data from the Phase 1 expansion data for NBTXR3 in head and neck cancer.
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) will host a webinar at 8 a.m., Tuesday, to provide a corporate update on clinical programs for its CY6463 in Alzheimer's disease with vascular pathology and mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes.
Trillium Therapeutics Inc. (NASDAQ:TRIL) will host its virtual R&D Day for analysts and investors at 10:00 am – 1:00 pm on Wednesday, wherein it will provide a clinical update for TTI-622 in refractory lymphoma or multiple myeloma, and TTI-621 in diffuse Large B-cell Lymphoma (DLBCL), cutaneous T-cell lymphoma.
Aptinyx Inc. (NASDAQ:APTX) is due to present at the SOBP annual meeting, data from the Phase 2a exploratory study of NYX-783 in posttraumatic stress disorder.
Annovis Bio, Inc. (NYSE:ANVS) is scheduled to release in April interim data for ANVS401 in Alzheimer's and Parkinson's diseases.
Lineage Cell Therapeutics, Inc. (NYSE:LCTX) is set to present at the ARVO annual meeting updated interim results from a Phase 1/2a study of its lead product candidate, OpRegen, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration.
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) (before the market open)Masimo Corporation (NASDAQ:MASI) (after the close)
Eli Lilly and Company (NYSE:LLY) (before the market open)AtriCure, Inc. (NASDAQ:ATRC) (after the close)Amgen Inc. (NASDAQ:AMGN) (after the close)Illumina, Inc. (NASDAQ:ILMN) (after the close)
Boston Scientific Corporation (NYSE:BSX) (before the market open)Surmodics, Inc. (NASDAQ:SRDX) (before the market open)Integra LifeSciences Holdings Corporation (NASDAQ:IART) (before the market open)Alkermes plc (NASDAQ:ALKS) (before the market open)Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) (after the close)Alimera Sciences, Inc. (NASDAQ:ALIM) (after the close)OPKO Health, Inc. (NASDAQ:OPK) (after the close)Hologic, Inc. (NASDAQ:HOLX) (after the close)Viking Therapeutics, Inc. (NASDAQ:VKTX) (after the close)
Syneos Health, Inc. (NASDAQ:SYNH) (before the market open)NovoCure Limited (NASDAQ:NVCR) (before the market open)West Pharmaceutical Services, Inc. (NYSE:WST) (before the market open)Merck & Co., Inc. (NYSE:MRK) (before the market open)Evelo Biosciences, Inc. (NASDAQ:EVLO) (before the market open)Baxter International Inc. (NYSE:BAX) (before the market open)Bristol-Myers Squibb Company (NYSE:BMY) (before the market open)Blueprint Medicines Corporation (NASDAQ:BPMC) (before the market open)Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) (before the market open)Laboratory Corporation of America Holdings (NYSE:LH) (before the market open)Abiomed, Inc. (NASDAQ:ABMD) (before the market open)Amarin Corporation plc (NASDAQ:AMRN) (before the market open)Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) (before the market open)ResMed Inc. (NYSE:RMD) (after the close) (after the close)MiMedx Group, Inc. (NASDAQ:MDXG) (after the close)BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) (after the close)Pacific Biosciences of California, Inc. (NASDAQ:PACB) (after the close)Bio-Rad Laboratories, Inc. (NYSE:BIO) (after the close)Emergent BioSolutions Inc. (NYSE:EBS) (after the close)ChemoCentryx, Inc. (NASDAQ:CCXI) (after the close)DexCom, Inc. (NASDAQ:DXCM) (after the close)Gilead Sciences, Inc. (NASDAQ:GILD) (after the close)Merit Medical Systems, Inc. (NASDAQ:MMSI) (after the close)LeMaitre Vascular, Inc. (NASDAQ:LMAT) (after the close)MacroGenics, Inc. (NASDAQ:MGNX) (after the close)Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (after the close)Seagen Inc. (NASDAQ:SGEN) (after the close)
AbbVie Inc. (NYSE:ABBV) (before the market open)
IPOs Quiet Period Expiries
Achilles Therapeutics plc (NASDAQ:ACHL)
Related Link: Why This Bristol-Myers Squibb Stock Analyst Is Turning Bullish On The Pharma Company's Pipeline
(RTTNews) - The Thai stock market has finished lower in four straight sessions, sliding more than 30 points or 2 percent along the way. The Stock Exchange of Thailand now rests just beneath the 1,560-point plateau although it's expected to stop the bleeding on Tuesday.
The global forecast for the Asian markets is mostly positive on optimism for earnings - especially tech shares - although coronavirus concerns in India may cap the upside. The European markets were up and the U.S. bourses were mixed and the Asian markets figure to follow suit.
The SET finished modestly higher on Monday following gains from the energy producers and a mixed picture from the financial sector.
For the day, the index rose 5.94 points or 0.38 percent to finish at 1,559.53 after trading between 1,544.10 and 1,561.52. Volume was 32.812 billion shares worth 83.672 billion baht. There were 1,0001 decliners and 636 gainers, with 425 stocks finishing unchanged.
Among the actives, Advanced Info dropped 0.86 percent, while Thailand Airport advanced 0.79 percent, Asset World tanked 2.99 percent, Bangkok Asset Management shed 0.49 percent, Bangkok Bank lost 0.41 percent, Bangkok Dusit Medical jumped 1.83 percent, Bangkok Expressway sank 0.62 percent, BTS Group skidded 1.11 percent, Charoen Pokphand Foods retreated 0.86 percent, Kasikornbank slid 0.38 percent, PTT Oil & Retail declined 1.67 percent, PTT Exploration and Production climbed 0.88 percent, PTT Global Chemical surged 3.24 percent, SCG Packaging added 0.51 percent, Siam Commercial Bank surrendered 0.96 percent, Siam Concrete spiked 1.40 percent, TMB Bank collected 0.86 percent and PTT, Gulf and Krung Thai Bank were unchanged.
The lead from Wall Street is mixed to higher as the major averages opened in the green on Monday although the Dow was unable to hold its gains at the end of the day.
The Dow slipped 61.92 points or 0.18 percent to finish at 33,981.57, while the NASDAQ jumped 121.97 points or 0.87 percent to end at 14,138.78 and the S&P 500 rose 7.45 points or 0.18 percent to close at 4,187.62.
Tech stocks led the markets higher amid optimism ahead of the release of quarterly results from a number of big-name companies later this week.
Buying interest was subdued, however, as traders looked ahead to the Federal Reserve's monetary policy announcement on Wednesday. The Fed is widely expected to maintain its ultra-easy monetary policy, but traders will be paying close attention to any changes to the accompanying statement that may signal a shift in the near future.
In economic news, the Commerce Department said new orders for U.S. manufactured durable goods increased by less than expected in March.
Crude oil prices drifted lower on Monday amid continues worries about the outlook for energy demand due to rising coronavirus cases in India. West Texas Intermediate Crude oil futures for June ended lower by $0.23 or 0.4 percent at $61.91 a barrel.